Stockscreener 앱 받기
4.88
2.40%
-0.12
시간 외 거래:
4.99
0.11
+2.25%
Evotec Se Adr 주식(EVO)의 최신 뉴스
In-Vitro Toxicology Testing Market Projected to Reach USD 30.06 Bn by 2033 - GlobeNewswire Inc.
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer By Investing.com - Investing.com South Africa
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
After-hours movers: Applied Materials, Domino's Pizza, Evotec - Investing.com
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Yahoo Finance
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Antibody Discovery Market Size Expected to Surge to USD 4.8 - GlobeNewswire Inc.
Evotec stock holds Buy rating with price target from TD Cowen By Investing.com - Investing.com India
Healthcare Sector - Morningstar
Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
QT to end this December with hardly a whimper: Barclays By Investing.com - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec: R&D, Customer Growth Not Enough To Offset Headwinds - Seeking Alpha
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq
1.43%
0.64%
자본화:
|
볼륨(24시간):